2012年
1. Sato K, Nakamura A, Shirakawa J, Muraoka T, Togashi Y, Shinoda K, Orime K, Kubota N, Kadowaki T, Terauchi Y. Impact of the dipeptidyl peptidase-4 inhibitor vildagliptin on glucose tolerance, beta cell function and mass in insulin receptor substrate-2-knockout mice fed a high-fat diet. Endocrinology, 153: 1093-1102, 2012.
2. Masuda K, Aoki K, Terauchi Y. Comparison of plasma active glucagon-like peptide-1 (GLP-1) levels assayed with or without plasma extraction in non-diabetic men. Endocr. J., 59(5): 435-8, 2012.
3. Nakamura A, Togashi Y, Orime K, Sato K, Shirakawa J, Ohsugi M, Kubota N, Kadowaki T, Terauchi Y. Control of beta cell function and proliferation in mice stimulated by small molecule glucokinase activator under various conditions. Diabetologia, 55(6): 1745-54, 2012.
4. Shirakawa J, Togashi Y, Tajima K, Orime K, Kikuchi K, Miyazaki T, Sato K, Kimura M, Goshima Y, Terauchi Y. Plasminogen activator inhibitor-1 is associated with renal dysfunction independent of BMI and serum lipid levels in patients with type 2 diabetes. Diabetes Res. Clin. Pract., 97(1): e7-e10, 2012.
5. Shigematsu E, Yamakawa T, Taguri M, Morita S, Tokui M, Miyamoto K, Funae O, Takatuka Y, Kadonosono K, Shigematsu H, Terauchi Y. Efficacy of ezetimibe is associated with gender and baseline lipid levels in patients with type 2 diabetes. J. Atheroscler. Thromb., 2012 Jul 11. [Epub ahead of print]
6. Namba M, Kaku K, Yoshioka N, Yamada Y, Wartada H, Ueki K, Terauchi Y, Tobe K, Araki E, Shuto T, Kadowaki T. The PREDICTIVE study: a multinational prospective observational study to evaluate the safety and efficacy of insulin detemir treatment in patients with type 1 and 2 diabetes – data from the Japan cohort. Diabetology Internatonal, 3: 11-20, 2012.
7. Shirakawa J, Tanami R, Togashi Y, Tajima K, Orime K, Kubota N, Kadowaki T, Goshima Y, Terauchi T. Effects of liraglutide on β cell-specific glucokinase-deficient neonatal mice. Endocrinology, 153(7): 3066-75, 2012.
8. Kubota A, Maeda H, Kanamori A, Matoba K, Jin Y, Minagawa F, Obana M, Iemitsu K,
Ito S, Amamiya H, Kaneshiro M, Takai M, Kaneshige H, Hoshino K, Ishikawa M, Minami N, Takuma T, Sasai N, Aoyagi S, Kawata T, Mokubo A, Takeda H, Honda M, Machimura H, Motomiya T, Waseda M, Naka Y, Tanaka Y, Terauchi Y, Matsuba I. Efficacy and safety of sitagliptin monotherapy and combination therapy in Japanese type 2 diabetes patients. J. Diabetes Invest., in press, 2012.
9. Kikuchi K, Nezu U, Inazumi K, Miyazaki T, Ono K, Orime K, Shirakawa J, Sato K, Koike H, Wakasugi T, Sato M, Kawakami C, Watanabe S, Yamakawa T, Terauchi Y. Double-blind randomized clinical trial of the effects of ezetimibe on postprandial hyperlipidaemia and hyperglycaemia. J. Atheroscler. Thromb., 2012 Aug 9 [Epub ahead of print]
10. Nakamura A, Tajima K, Zolzaya K, Sato K, Inoue R, Yoneda M, Fujita K, Nozaki Y, Kubota KC, Haga H, Kubota N, Nagashima Y, Nakajima A, Maeda S, Kadowaki T, Terauchi Y. Protection from nonalcoholic steatohepatitis and liver tumorigenesis in high fat-fed insulin receptor substrate-1-knockout mice despite insulin resistance. Diabetologia, 2012 Sep.7 [Epub ahead of print]
11. Nakamura A, Terauchi Y. Factors associated with the glucose-lowering effect of vildagliptin identified from the results of the oral glucose tolerance test in Japanese patients with type 2 diabetes. Endocr. J., 2012 Sep 9 [Epub ahead of print]
12. Goto M, Morita A, Goto A, Sasaki S, Aiba N, Shimbo T, Terauchi Y, Miyachi M, Noda M, Watanabe S. Dietary glycemic index and glycemic load in relation to HbA1c in Japanese obese adults: a cross-sectional analysis of the Saku Control Obesity Program. Nutr. Metab. (Lond), 2012 Sep 10;9(1):79. [Epub ahead of print]
13. Kubota A, Maeda H, Kanamori A, Matoba K, Jin Y, Minagawa F, Obana M, Iemitsu K, Ito S, Amemiya H, Kaneshiro M, Takai M, Kaneshige H, Hoshino K, Ishikawa M, Minami N, Takuma T, Sasai N, Aoyagi S, Kawata T, Mokubo A, Takeda H, Honda S, Machimura H, Motomiya T, Waseda M, Naka Y, Tanaka Y, Terauchi Y, Matsuba I .Pleiotropic effects of sitagliptin in the treatment of type 2 diabetes mellitus patients. J. Clin. Med. Res., 4(5):309-13, 2012.
14. Goto A, Morita A, Goto M, Sasaki S, Miyachi M, Aiba N, Terauchi Y, Noda M, Watanabe S. Associations of sex hormone-binding globulin and testosterone with diabetes among men and women (the Saku Diabetes study): a case control study. Cardiovasc. Diabetol., 2012 Oct 16;11(1):130. [Epub ahead of print]
15. Orime K, Shirakawa J, Togashi Y, Tajima K, Inoue H, Ito Y, Sato K, Nakamura A, Aoki K, Goshima Y, Terauchi Y. Trefoil factor 2 promotes cell proliferation in pancreatic β cells through CXCR-4-mediated ERK1/2 phosphorylation. Endocrinology, 2012 Nov 26. [Epub ahead of print]
16. Aoki K, Kamiyama H, Masuda K, Togashi Y, Terauchi Y. Mosapride citrate, a 5-HT4 receptor agonist, increased the plasma active and total glucagon-like peptide-1 levels in non-diabetic men. Endocr. J., in press, 2012.
2011年
1. Sekino Y, Iida H, Endo H, Sakamoto Y, Yoneda M, Koide T, Takahashi H, Tokoro C, Abe Y, Nakajima A, Maeda S, Takihata M, Terauchi Y and Inamori M: Effectiveness of repeated intragastric balloon therapy in a morbidly obese Japanese patient. Intern. Med., 50: 109-112, 2011.
2. Goto M, Yamamoto-Honda R, Shimbo T, Goto A, Terauchi Y, Kanazawa Y, and Noda M: Correlation between baseline serum 1,5-anhydroglucitol levels and 2-hour post-challenge glucose levels during oral glucose tolerance tests. Endocr. J., 58: 13-17, 2011.
3. Kubota T, Kubota N, Kumagai H, Yamaguchi S, Kozono H, Takahashi T, Inoue M, Itoh S, Takamoto I, Sasako T, Kumagai K, Kawai T, Hashimoto S, Kobayashi T, Sato M, Tokuyama K, Nishimura S, Tsunoda M, Ide T, Murakami K, Yamazaki T, Ezaki O, Kawamura K, Masuda H, Moroi M, Sugi K, Oike Y, Shimokawa H, Yanagihara N, Tsutsui M, Terauchi Y, Tobe K, Nagai R, Kamata K, Inoue K, Kodama T, Ueki K, Kadowaki T. Impaired insulin signaling in endothelial cells reduces insulin-induced glucose uptake by skeletal muscle. Cell Metab., 13: 294-307, 2011.
4. Shirakawa J, Fujii H, Ohnuma K, Sato K, Ito Y, Kaji M, Sakamoto E, Koganei M, Sasaki H, Nagashima Y, Amo K, Aoki K, Morimoto C, Takeda E and Terauchi Y: Diet-induced adipose tissue inflammation and liver steatosis are prevented by DPP-4 inhibition in diabetic mice Diabetes, 2011 Feb 17. [Epub ahead of print]
5. Yamakawa T, Kaneko T, Shigematsu E, Kawaguchi J, Kadonosono K, Morita S, and Terauchi Y. Glucose-lowering effect of colestimide is associated with baseline HbA1c in type 2 diabetic patients with hypercholesterolemia. Endocr. J., 2011 Feb 22. [Epub ahead of print]
6. Kawasaki S, Satoh S, Hasegawa O, Morita S, Kato S, and Terauchi Y. Female preponderance in the discordant association between retinopathy and nephropathy in patients with Type 2 diabetes mellitus Int. J. Clin. Med., in press, 2011
7. Shihara N, Kitaoka M, Inagaki N, Kadowaki T, Koumoto S, Satoh J, Terauchi Y, Nunoi K, Yamada Y, Sakamaki H, and Seino Y. Randomized controlled trial of single-agent glimepiride and pioglitazone in Japanese patients with type 2 diabetes comparative study head to head. J. Diabetes Invest., in press, 2011.
8. Tanaka T, Gjonça E, Gulliford MC. Income, wealth and risk of diabetes among older adults: cohort study using the English Longitudinal Study of Aging. Eur. J. Pub. Health, in press, 2011.
9. Masuda K, Aoki K, Terauchi Y. Effects of miglitol taken just before or after breakfast on plasma glucose, serum insulin, glucagon and incretin levels after lunch in men with normal glucose tolerance (NGT), impaired fasting glucose (IFG) or impaired glucose tolerance (IGT). J. Diabetes Invest., in press, 2011.
10. Masuda K, Aoki K, Togashi Y, Takahashi M, Terauchi Y. Comparison of short-term effectiveness of introducing insulin treatment between intensive and thrice-daily lispro 50/50 therapy. Yokohama Med. J., in press, 2011.
11. Tsujimoto T, Takaichi M, Endo H, Yasuda K, Kishimoto M, Noto H, Gomibuchi H, Yasuda H, Yamamoto-Honda R, Takahashi Y, Kajio H, Sasano H, Noda M. A patient with diabetes and breast cancer in whom virilization was caused by a testosterone-producing mature cystic teratoma containing a Brenner tumor. Am. J. Med. Sci., 341(1): 74-77, 2011.
12. Tanaka T, Morita A, Kato M, Hirai T, Mizoue T, Terauchi Y, Watanabe S, Noda M, for the SCOP Study Group. Congener-specific polychlorinated biphenyls and the prevalence of diabetes in the Saku Control Obesity Program. Endocr. J., 2011 May 7. [Epub ahead of print]
13. Nakamura A, Yoneda M, Fujita K, Tajima K, Kikuchi K, Nakajima A, Maeda S and Terauchi Y. Impact of Glucose Tolerance on the Severity of Nonalcoholic Steatohepatitis. J. Diabetes Invest., in press, 2011.
14. Shirakawa J, Amo K, Ohminami H, Orime K, Togashi Y, Ito Y, Tajima K, Koganei M, Sasaki H, Takeda E, Terauchi Y. Protective effect of a dipeptidyl peptidase-4 (DPP-4) inhibitor against increased β cell apoptosis induced by dietary sucrose and linoleic acid in mice with diabetes. J. Biol. Chem., 286(29): 25467-76, 2011.
15. Iwasaki T, Yoneda M, Terauchi Y, et al. Sitagliptin as a novel treatment agent for non-alcoholic fatty liver disease patients with type-2 diabetes mellitus. Hepatogastroenterology, 58(112). doi: 10.5754/hge11263. [Epub ahead of print]
16. Yamazaki T, Kishimoto J, Ito C, Noda M, Odawara M, Terauchi Y, Shiba T, Kitazato H, Iwamoto Y, Akanuma Y, Kadowaki T, for the J-PREDICT Study investigators. The J-PREDICT Study, Japan Prevention Trial of Diabetes by Pitavastatin in Patients with Impaired Glucose Tolerance: Rationale, Study Design and Clinical Characteristics of 1,269 Patients. Diabetology International, in press, 2011.
17. Sekino Y, Imajo K, Sakai E, Uchiyama T, Iida H, Endo H, Hosono K, Sakamoto Y, Fujita K, Yoneda M, Takahashi H, Koide T, Tokoro C, Abe Y, Saito S, Maeda S, Gotoh E, Takihata M, Terauchi Y, Nakajima A, Inamori M. Time-course of changes of visceral fat area, liver volume and liver fat area during intragastric balloon therapy in Japanese super-obese patients. Intern. Med., 50(21):2449-55, 2011.
18. Cheng C, Nakamura A, Minamimoto R, Shinoda K, Tateishi U, Goto A, Kadowaki T, Terauchi T, and Inoue T: Evaluation of organ-specific glucose metabolism by (18)F-FDG in insulin receptor substrate-1 (IRS-1) knockout mice as a model of insulin resistance. Ann. Nucl. Med., 2011 Aug 5. [Epub ahead of print]
19. Aoki K, Kamiyama H, Yoshimura K, Shibuya M, Masuda K, and Terauchi Y. Miglitol administered before breakfast increased plasma active glucagon-like peptide-1 (GLP-1) levels after lunch in patients with Type 2 diabetes treated with sitagliptin. Acta. Diabetol., 2011 Sep 6. [Epub ahead of print]
20. Goto A, and Liu S. Is caffeine protective against Type 2 diabetes? Diabetes Manage, 1(4): 351–353, 2011. (Editorial)
21. Aoki K, and Terauchi Y. Effect of acarbose therapy once or twice a day on glycemic control in Japanese patients with type 2 diabetes. J. Pharmacol. Sci., in press, 2011.
22. Jin Y, Kanamori A, Ito S, Matoba K, Miyakawa M, Kaneshige H, Obana M, Takai M, Takeda H, Machimura H, Minami N, Kawada T, Honda M, Aoyagi S, Amamiya H, Sasai N, Nakayama M, Naka Y, Terauchi Y, and Matsuba I. Cross-sectional survey of diabetic neuropathy in Kanagawa and clinical significance of a touch test using tissue paper. J. Diabetes Invest., in press, 2011.
23. Maeda H, Kubota A, Tanaka Y, Terauchi Y, Matsuba I, ASSET-K Study group. The safety, efficacy and predictors for HbA1c reduction of sitagliptin in the treatment of Japanese type 2 diabetes. Diabetes Res. Clin. Pract., 2011 Nov 2. [Epub ahead of print]
24. Iwasaki T, Tomeno W, Yoneda M, Inamori M, Shirakawa J, Imajo K, Kawashima K, Terauchi Y, Nakajima A. Nonalcoholic fatty liver disease adversely affects the glycemic control afforded by sitagliptin. Hepatogastroenterology, in press, 2011.
25. Arai K, Masahiko M, Hirao K, Matsuba I, Matoba K, Takeda H, Kanamori A, Yamauchi M, Mori H, Terauchi Y. Present status of insulin therapy for type 2 diabetes treated by general practitioners and diabetes specialists in Japan: Third report of a cross-sectional survey of 15652 patients. J. Diabetes Invest., in press, 2011.
2010年
1. Okazaki, Y., Eto, K., Yamshita, T., Okamoto, M., Ohsugi, M., Noda, M., Terauchi, Y., and Kadowaki, T. Decreased insulin secretion and accumulation of triglyceride in -cells overexpressing a dominant-negative form of AMP-activated protein kinase. Endocr. J., 57(2): 141-152, 2010.
2. Kikuchi, K., Nezu, U., Shirakawa, J., Sato, K., Togashi, Y., Kikuchi, T., Aoki, K., Ito, Y., Kimura, M., and Terauchi, Y. Correlations of fasting and postprandial blood glucose increments to the overall diurnal hyperglycemic status in type 2 diabetic patients: Variations with levels of HbA1c Endocr. J., 57(3): 259-266, 2010.
3. Fujita, K., Nozaki, Y., Yoneda, M., Wada, K., Takahashi, H., Kirikoshi, H., Inamori, M., Saito, S., Iwasaki, T., Terauchi, Y., Maeyama, S., and Nakajima, A.: Nitric oxide plays a crucial role in the development/progression of nonalcoholic steatohepatitis in the choline-deficient, l-amino acid-defined diet-fed rat model. Alcohol Clin. Exp. Res., 34 Suppl 1:S18-24, 2010.
4. Arai, K., Matoba, K., Hirao, K., Matsuba, I., Takai, M., Takeda, H., Kanamori, A., Yamauchi, M., Mori, H., and Terauchi, Y. : Present status of sulfonylurea treatment for type 2 diabetes in Japan: Second report of a cross-sectional survey of 15,652 patients. Endocr. J., 57: 499-507, 2010.
5. Aoki, K., Muraoka, T., Ito, Y. Togashi, Y., and Terauchi, Y. : Comparison of adverse gastrointestinal effects of acarbose and miglitol in healthy men: A crossover study. Intern. Med., 49: 1085-1087, 2010.
6. Masuda, K., Aoki, K., Kikuchi, K., Nezu, U., Muraoka, T., Shinoda, K., Nakamura, A., Shibuya, M., Takahashi, M., Kimura, M., and Terauchi, Y. : Self-injection of insulin using appropriate supportive devices in handicapped subjects with diabetes. Diabetes Technol. Ther., 12(6): 483-490, 2010.
7. Yoneda, M., Fujita, K., Nozaki, Y., Endo, H., Takahashi, H., Hosono, K., Suzuki, K., Mawatari, H., Kirikoshi, H., Inamori, M., Saito, S., Iwasaki, T., Terauchi, Y., Kubota, K., Maeyama, S., and Nakajima, A. : Efficacy of ezetimibe for the treatment of non-alcoholic steatohepatitis: An open-label, pilot study. Hepatol. Res., 40: 613-621, 2010.
8. Nezu, U., Tsunoda, S., Yoshimura, H., Kuwabara, T., Tomura, S., Seki, Y., Kaneshiro, M., Kamiyama, H., Harada, Y., Shigematsu, E., Aoki, K., Yamakawa, T., Ohshige, K., and Terauchi, Y. : Pravastatin potentiates increases in serum adiponectin concentration in dyslipidemic patients receiving thiazolidinedione: the DOLPHIN Study. J. Atheroscler. Thromb., 17: 1063-1069, 2010.
9. Aoki, K., Masuda, K., Miyazaki, T., Togashi, Y., and Terauchi, Y. : Effects of miglitol, sitagliptin or their combination on plasma glucose, insulin and incretin levels in non-diabetic men. Endocr. J., 57: 667-672, 2010.
10. Aoki, K., Miyazaki, T., Nagakura, J., Orime, K., Togashi, Y., and Terauchi, Y. : Effects of pre-meal versus post-meal administration of miglitol on plasma glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide levels in healthy men. Endocr. J., 57: 673-677, 2010.
11. Nakamura, A., Osonoi, H., and Terauchi, Y. : Relationship between urinary sodium excretion and pioglitazone-induced edema. J. Diabetes Invest., in press, 2010.
12. Muraoka, T., Aoki, K., Iwasaki, T., Shinoda, K., Nakamura, A., Aburatani, H., Mori, S., Tokuyama, K., Kubota, N., Kadowaki, T., and Terauchi, T. : Ezetimibe decreases SREBP-1c expression in liver and reverses hepatic insulin resistance in mice fed a high-fat diet. Metabolism, 2010 July 31. [Epub ahead of print]
13. Kawasaki, S., Hasegawa, O., Satoh, S., Numata, K., and Terauchi, Y. : Sonographic assessment of fatty liver infiltration using the measurement of para- and perirenal fat thickness. J. Clin. Ultrasound., 2010 Aug 30. [Epub ahead of print]
14. Goto A, Takaichi M, Kishimoto M, Takahashi Y, Kajio H, Shimbo T, and Noda M. : Body mass index, fasting plasma glucose levels, and C-peptide levels as predictors of the future insulin use in Japanese type 2 diabetic patients. Endocr. J., 57: 237-244, 2010.
15. Takarabe D, Rokukawa Y, Takahashi Y, Goto A, Takaichi M, Okamoto M, Tsujimoto T, Noto H, Kishimoto M, Kaburagi Y, Yasuda K, Yamamoto-Honda R, Tsukada K, Honda M, Teruya K, Kajio H, Kikuchi Y, Oka S, and Noda M. : Autoimmune diabetes in HIV-infected patients on highly active antiretroviral therapy. J. Clin. Endocrinol. Metab. 95: 4056-4060, 2010.
16. Goto A, Song Y, Chen B, Manson J, Buring J, and Liu S. : Coffee and caffeine consumption in relation to sex hormone-binding globulin and risk of type 2 diabetes in postmenopausal women. Diabetes, 2010 Oct 28. [Epub ahead of print]
17. Goto, M., Yamamoto-Honda, R., Shimbo, T., Goto, A., Terauchi, Y., Kanazawa, Y., and Noda, M. : Correlation between baseline serum 1,5-anhydroglucitol levels and 2-hour post-challenge glucose levels during oral glucose tolerance tests. Endocr. J., in press, 2010.
18. Ito Y, Yoshimura K, Matsuzawa Y, Saito J, Ito H, Furukawa H, Okura K, Fukata M, Konishi T and Nishikawa T: Successful treatment of a mycotic aortic pseudoaneurysm in a patient with type 2 diabetes mellitus while treating primary aldosteronism with spironolactone. J. Atheroscler. Thromb., 17: 771-775, 2010.
19. Sekino Y, Iida H, Endo H, Sakamoto Y, Yoneda M, Koide T, Takahashi H, Tokoro C, Abe Y, Nakajima A, Maeda S, Takihata M, Terauchi Y, and Inamori M: Effectiveness of repeated intragastric balloon therapy in a morbidly obese Japanese patient. Intern. Med., in press, 2010.
20. Kaneko K, Ueki K, Takahashi N, Hashimoto S, Okamoto M, Awazawa M, Okazaki Y, Ohsugi M, Inabe K, Umehara T, Yoshida M, Kakei M, Kitamura T, Luo J, Kulkarni RN, Kahn CR, Kasai H, Cantley LC, Kadowaki T: Class IA phosphatidylinositol 3-kinase in pancreatic β cells controls insulin secretion by multiple mechanisms. Cell Metab., 12(6): 619-632, 2010.
21. Nakamura A, Hiroko Shimazaki H, Ohyama S, Eiki J, and Terauchi Y: Effect of long-term treatment with a small molecule glucokinase activator on glucose metabolism, lipid profiles, and hepatic function. J. Diabetes Invest., in press, 2010.
22. Shirakawa J, Fujii H, Ohnuma K, Sato K, Ito Y, Kaji M, Sakamoto E, Koganei M, Sasaki H, Nagashima Y, Amo K, Aoki K, Kubota N, Kadowaki T, Morimoto C, Takeda E and Terauchi Y: Diet-induced adipose tissue inflammation and liver steatosis are prevented by DPP-4 inhibition in diabetic mice Diabetes, in press, 2010.
23. Saito J, Matsuzawa Y, Ito H, Omura M, Ito Y, Yoshimura K, Yajima Y, Kino T, Nishikawa T. The alkalizer citrate reduces serum uric Acid levels and improves renal function in hyperuricemic patients treated with the xanthine oxidase inhibitor allopurinol. Endocr. Res., 35(4): 145-154, 2010.